Ranbaxy Laboratories has decided to separate the two areas of research and development - drug discovery and generics/NDDS/drug development - to achieve increased focus and rigour for success.
According to a release issued by the company to the Bombay Stock Exchange on Friday, the move follows the return of Dr Rajinder Kumar, erstwhile head (R&D) of Ranbaxy, to the UK.
"The company has reluctantly agreed to his request due to personal circumstances. He will be invited to join Ranbaxy's R&D advisory council in due course," the release added.
Dr Brian Tempest, CEO and MD of Ranbaxy, said, "We acknowledge the role Dr Rajinder Kumar has played in institutionalising the R&D regimen, in particular the clinical processes at Ranbaxy."
The company continues to be on a strong footing in this area. The new structure is designed to bring into sharper focus the unique needs of drug discovery and generics research while emphasising both equally, he added.
Dr Vijay Batra will now lead the generics/NDDS/drug development research efforts of the company, and will report to Dr Tempest.
"Dr Batra is credited with having progressed the development of the anti-malaria molecule, RBX 11160, to Phase II clinical trials. He has also worked on the development of the Ranbaxy Atorvastatin product," the release said.
Dr Kasim Mookhtiar, who is in charge of drug discovery, will also report to Dr. Tempest, the release added.
© 2025